Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Standalone and Consolidated ....

Date: 21st July, 2026 To, To, BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 Ref.: BSE Scrip Code No. “533138” Ref.: “ASTEC” Debt Segment NSE: NCD-ASTEC-ISIN: INE563J08023 Sub.: Intimation of Board Meeting as per Regulations 29 and 50(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, Notice is hereby given pursuant to Regulations 29 and 50(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), that the Meeting of the Board of Directors of Astec LifeSciences Limited (“the Company”) is scheduled to be held on Friday, 31st July, 2026, to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2026, after these Results are reviewed by the Audit Committee. The copy of the intimation is also available on the website of the Company (www.godrejastec.com). We request you to please take the above information on your records. Thanking you, Yours sincerely, For Astec LifeSciences Limited Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)